[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"University of Chicago\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":618},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,174,0,25,[9,42,73,103,127,154,178,205,225,246,266,291,319,339,360,380,405,436,456,479,500,529,559,570,591],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":29,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":4},"100053444","big-chicago-a-trial-of-basic-income-guarantee-for-young-people-living-with-hiv-100053444",false,"NCT07502365","BIG Chicago: A Trial of Basic Income Guarantee for Young People Living With HIV","Inclusion Criteria:\n\n* Living with HIV for 24 months or longer;\n* Ages 18-35;\n* English-speaking;\n* One or both of the following:\n\n  1. Experienced a gap in HIV provider care of 6 or greater months during the prior 12-month period;\n  2. Had an unsuppressed viral load at any point within the prior 12-month period (unsuppressed meaning a viral load of 200 copies\u002FmL or higher);\n* Household income at or below 250% of the Federal Poverty Level; and\n* Experiencing financial distress, as based on a financial well-being score of 1-4 (high financial distress).\n\nExclusion Criteria:\n\n* Unwilling\u002Funable to provide informed consent\n* Unable to confirm HIV status\n* Unable to conduct the study in English","ALL","18 Years","35 Years",{"count":20,"type":21},304,"ESTIMATED","INTERVENTIONAL",[24],"NA","The goal of this clinical trial is to compare two interventions - Basic Income Guarantee (BIG) + Treatment as Usual and Treatment as Usual among individuals living with HIV who have experienced financial hardships.\n\nThe main question it aims to answer is:\n\nCompared with the Treatment as Usual group, will participants in the BIG + Treatment as Usual group be more likely to improve care engagement and viral suppression?\n\nParticipants on the study will be:\n\n* Randomly assigned (like the flip of a coin) to participate in either BIG + Treatment as Usual or Treatment as Usual. Participants will have an equal chance of being placed in either group.\n* Complete 9 surveys over a 36 month period.\n* Complete a release of information so electronic medical record data can be accessed for the 18 months prior to treatment engagement and for 36 months from program enrollment.\n* Participants in the Treatment as Usual group will not receive any intervention.\n* HIV viral load testing will be confirmed at 3 timepoints (baseline, 12 months, and 18 months).\n* Participants in the BIG + Treatment as Usual group will receive $500 monthly income for 18 months.\n* Participants in the BIG + Treatment as Usual group will complete 3 social network surveys to assess how receiving BIG impacts their social networks.\n* A subset of participants in the BIG + Treatment as Usual group (30 participants) will complete 5 individual interviews over the course of receiving BIG and the 18 months after.",[27,28],"HIV","Financial Stress",[27,28],"NOT_YET_RECRUITING","2026-07-10",{"date":33,"type":34},"2026-07-13","ACTUAL",{"date":36,"type":21},"2026-07",{"date":38,"type":21},"2030-07",{"name":40,"class":41},"University of Chicago","OTHER",{"id":43,"slug":44,"hasResults":12,"nctId":45,"briefTitle":46,"officialTitle":47,"acronym":48,"eligibilityCriteria":49,"healthyVolunteers":12,"sex":50,"minAge":17,"maxAge":4,"enrollmentInfo":51,"targetDuration":53,"studyType":54,"phases":4,"briefSummary":55,"conditions":56,"keywords":58,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":67,"startDateStruct":68,"completionDateStruct":69,"leadSponsor":71,"locationsCount":72},"100054029","outpatient-visits-versus-telehealth-for-postoperative-care-after-minimally-invasive-gynecologic-surgery-100054029","NCT07420114","Outpatient Visits Versus Telehealth for Postoperative Care After Minimally Invasive Gynecologic Surgery","Outpatient Visits Versus Telehealth for Postoperative Care After Minimally Invasive Gynecologic Surgery: A Randomized Controlled Trial","Telehealth RCT","Inclusion Criteria:\n\n1. Participant has provided written informed consent.\n2. Women over the age of 18.\n3. Ability for patients to complete telehealth visits (i.e. working telephone or internet access) and speak and understand English.\n4. Laparoscopic or robotic surgeries including: excision of endometriosis, adnexal surgery with oophorectomy or cystectomy, myomectomy, and hysterectomy.\n5. Undergoing minimally invasive gynecologic surgeries with complex pelvic surgeons (AAGL fellowship-trained).\n\nExclusion Criteria:\n\n1. Conversion to open surgery.\n2. Malignancy noted intraoperatively or on final pathology evaluation.\n3. Surgeon or patient preference for in person clinic follow up.\n4. Pregnancy - pregnancy tests will be completed as part of routine preoperative care on the day of surgery","FEMALE",{"count":52,"type":21},100,"3 Months","OBSERVATIONAL","Telehealth, or telemedicine, utilizes technology to deliver clinical care remotely, either in real time or asynchronously, between clinician and patient. Telemedicine has been successfully implemented to increase healthcare delivery for patients in rural areas with otherwise long travel times, and studies have also determined that telemedicine can increase patient satisfaction scores while simultaneously decreasing direct and indirect costs for patients.\n\nPrevious scholarship has demonstrated that telemedicine can be a safe alternative to face-to-face postoperative visits for surgical patients, streamlining recovery with no significant delays in the diagnosis of surgical complications. As healthcare systems continue to emphasize value-based care, it is important to assess whether virtual postoperative visits effectively meet patient needs while optimizing resource utilization.\n\nPatient-reported outcomes and satisfaction surveys can help identify potential gaps in care and ensure that telehealth is implemented in a way to maximize both efficiency and quality. Our primary objective is to determine whether patient satisfaction with postoperative telehealth follow-up is non-inferior to in-person clinic visits.",[57],"to Determine Whether Patient Satisfaction With Postoperative Telehealth Follow-up is Non-inferior to In-person Clinic Visits",[59,60,61,62,63,64,65,66],"telehealth","minimally invasive gynecologic surgery","hysterectomy","myomectomy","excision of endometriosis","laparoscopic surgeries","robotic surgeries","adnexal surgery",{"date":33,"type":34},{"date":36,"type":21},{"date":70,"type":21},"2026-12",{"name":40,"class":41},2,{"id":74,"slug":75,"hasResults":12,"nctId":76,"briefTitle":77,"officialTitle":78,"acronym":4,"eligibilityCriteria":79,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":80,"targetDuration":4,"studyType":22,"phases":82,"briefSummary":83,"conditions":84,"keywords":86,"overallStatus":96,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":97,"startDateStruct":98,"completionDateStruct":100,"leadSponsor":102,"locationsCount":72},"100054228","volume-supportassist-control-mode-ventilation-and-diaphragmatic-atrophy-100054228","NCT03901924","Volume Support\u002FAssist Control Mode Ventilation and Diaphragmatic Atrophy","A Phase III Randomized Trial Comparing the Effects of Volume Support and Assist Control Mode Ventilation on Ventilator-Free Days and Diaphragmatic Atrophy","Inclusion Criteria:\n\nsubjects \\> 18 years of age that have been intubated and mechanically ventilated for \\\u003C 36 hours at the time of screening will be eligible for enrollment\n\nExclusion Criteria:\n\n1. pregnancy\n2. cardiopulmonary arrest\n3. history of diaphragmatic paralysis or neuromuscular disease\n4. chronic obstructive pulmonary disease (COPD) or asthma exacerbation with evidence of auto-PEEPing requiring intubation\n5. neuromuscular blockade\n6. expectation to be liberated from ventilator in \\\u003C 24 hours\n7. history of mechanical ventilation in the last 6 months\n8. presence of tracheostomy\n9. high cervical spine injury",{"count":81,"type":21},468,[24],"The objective of the study is to determine how controlled mode ventilation and support mode ventilation impact ventilator-free days and diaphragmatic atrophy.",[85],"Mechanical Ventilation Complication",[87,88,89,90,91,92,93,94,95],"Diaphragm Atrophy","Ventilator Induced Diaphragm Dysfunction","Mechanical Ventilation","Volume Support Mode","Assist Control Mode","Diaphragm Thickening Fraction","Intubation","Delirium","Ventilator-Free Days","RECRUITING",{"date":33,"type":34},{"date":99,"type":34},"2019-03-04",{"date":101,"type":21},"2027-05",{"name":40,"class":41},{"id":104,"slug":105,"hasResults":12,"nctId":106,"briefTitle":107,"officialTitle":108,"acronym":4,"eligibilityCriteria":109,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":110,"enrollmentInfo":111,"targetDuration":4,"studyType":22,"phases":113,"briefSummary":115,"conditions":116,"keywords":4,"overallStatus":96,"whyStopped":4,"lastUpdateSubmitDate":119,"lastUpdatePostDateStruct":120,"startDateStruct":122,"completionDateStruct":124,"leadSponsor":126,"locationsCount":72},"100329599","phase-1-ruxolitinib-and-chemotherapy-in-adolescents-and-young-adults-with-ph-like-acute-lymphoblastic-leukemia-100329599","NCT03571321","Ruxolitinib and Chemotherapy in Adolescents and Young Adults With Ph-like Acute Lymphoblastic Leukemia","Phase I Trial of Ruxolitinib in Combination With a Pediatric Based-regimen for Adolescents and Young Adults (AYAs) With Ph-like Acute Lymphoblastic Leukemia (ALL)","Inclusion Criteria:\n\n* Newly diagnosed de novo B-precursor acute lymphoblastic leukemia (ALL) as determined by World Health Organization (WHO) criteria. Patients must have unequivocal diagnosis of precursor B ALL. This includes an institutional immunophenotyping report that is to assign B-lineage or T-lineage.\n* \"Ph-like\" signature, as determined by low density micro-array (LDA) card\n* Jak-targetable genetic signature as defined by any of the following:\n\n  * Cytokine receptor-like factor 2 (CRLF2) rearranged (JAK2 mutant or wild-type)\n  * JAK2 or erythropoietin receptor (EPOR) fusions.\n  * Other JAK pathway alterations at the discretion of the principle investigator including, but not limited to:\n* SH2B adaptor protein 3 (SH2B3) deletions\n* Interleukin-7 receptor subunit alpha (IL7RA) mutations\n* Prior therapy\n\n  * Prior to starting ruxolitinib, patients must have completed a 4-drug induction regimen with intrathecal chemotherapy (modified aBFM regimen or equivalent) as per the institutional standard of care. Recommended induction treatment is outlined in Section 5.1.2.\n  * No additional prior therapy for acute leukemia except emergency therapy (corticosteroids or hydroxyurea) for blast cell crisis, superior vena cava syndrome, or renal failure due to leukemic infiltration of the kidneys. When indicated, leukapheresis or exchange transfusion is recommended to reduce the white blood cell count (WBC).\n  * Screening may occur at any point prior to or during induction therapy\n* Age ≥ 18 years and \\\u003C 40 years. Because this is specifically a study of the adolescent and young adult population and no adverse event data are currently available on the use of this pediatric-based chemotherapy regimen in patients ≥ 40 years of age, older adults are excluded from this study, but may be eligible for future trials.\n* Eastern Cooperative Oncology Group (ECOG) performance status ≤2 (Karnofsky ≥ 60%)\n* Platelet count \\> 25,000\u002FuL.\n* Patients must have normal organ function as defined below:\n\n  * total bilirubin ≤ 2 mg\u002FdL\n  * aspartate aminotransferase (AST) \u002F alanine aminotransferase (ALT) ≤ 2.5 × institutional upper limit of normal\n  * creatinine within normal institutional limits OR creatinine clearance ≥ 60 mL\u002Fmin\u002F1.73 m2 for patients with creatinine levels above institutional normal.\n* Because the therapeutic agents used in this study are known to be teratogenic, women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation. Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately. Men treated or enrolled on this protocol must also agree to use adequate contraception prior to the study, for the duration of study participation.\n* Ability to understand and the willingness to sign a written informed consent document.\n\nExclusion Criteria:\n\n* Patients who are receiving any other investigational agent.\n* Patients with a \"currently active\" second malignancy other than non-melanoma skin cancers. Patients are not considered to have a \"currently active\" malignancy if they have completed therapy and are free of disease for ≥ 3 years.\n* History of allergic reactions attributed to compounds of similar chemical or biologic composition to ruxolitinib or other agents used in study.\n* Use of any potent cytochrome P450 (CYP) 3A4 inhibitor or inducer within 5 half-lives before the first dose of the study drug. Potent inhibitors of CYP3A4 include systemic ketoconazole, posaconazole, voriconazole, clarithromycin, itraconazole, nefazodone, and telithromycin. At the fluconazole dose of 200mg daily used this regimen, there is minimal inhibition of CYP3A4 \\[36\\] and therefore fluconazole is not prohibited on this trial and no dose modifications should be made in the presence of fluconazole.\n\nBecause the lists of these agents are constantly changing, it is important to regularly consult a frequently-updated list such as http:\u002F\u002Fmedicine.iupui.edu\u002Fclinpharm\u002Fddis\u002Ftable.aspx; medical reference texts such as the Physicians' Desk Reference may also provide this information. As part of the enrollment\u002Finformed consent procedures, the patient will be counseled on the risk of interactions with other agents, and what to do if new medications need to be prescribed or if the patient is considering a new over-the-counter medicine or herbal product.\n\n* Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness\u002Fsocial situations that would limit compliance with study requirements.\n* Pregnant women are excluded from this study because ruxolitinib is a class C agent with the potential for teratogenic or abortifacient effects. Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with ruxolitinib breastfeeding should be discontinued if the mother is treated with ruxolitinib. These potential risks may also apply to other agents used in this study.\n* Down Syndrome due to the likelihood of excessive toxicity resulting. These patients should be treated in consultation with a pediatric oncologist.\n* Burkitt type leukemia\n* Ph+ ALL at time of diagnosis","39 Years",{"count":112,"type":21},15,[114],"PHASE1","This study will test if adding ruxolitinib to standard multi-drug chemotherapy regimen will be safe and tolerated in adolescents and young adults with newly diagnosed Ph-like acute lymphoblastic leukemia (ALL).",[117,118,16],"Acute Lymphoblastic Leukemia","ALL, Childhood","2026-06-24",{"date":121,"type":34},"2026-06-29",{"date":123,"type":34},"2019-05-28",{"date":125,"type":21},"2027-09-05",{"name":40,"class":41},{"id":128,"slug":129,"hasResults":12,"nctId":130,"briefTitle":131,"officialTitle":131,"acronym":4,"eligibilityCriteria":132,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":133,"targetDuration":4,"studyType":22,"phases":135,"briefSummary":137,"conditions":138,"keywords":140,"overallStatus":96,"whyStopped":4,"lastUpdateSubmitDate":145,"lastUpdatePostDateStruct":146,"startDateStruct":148,"completionDateStruct":150,"leadSponsor":152,"locationsCount":153},"100644533","phase-1-total-intravenous-anesthesia-vs-spinal-anesthesia-in-patients-undergoing-unilateral-primary-total-knee-arthroplasty-100644533","NCT07672301","Total Intravenous Anesthesia vs Spinal Anesthesia in Patients Undergoing Unilateral Primary Total Knee Arthroplasty","Inclusion Criteria:\n\n* Adults aged ≥18 years.\n* Scheduled to undergo elective primary total knee arthroplasty (TKA) or robotic total knee arthroplasty (TKA) at the University of Chicago.\n* Eligible for same-day discharge (SDD) based on established orthopedic and anesthesia criteria.\n* Able to provide written informed consent.\n* The ability to comprehend and complete cognitive assessment surveys and questionnaires.\n* Consent to receive either Total IntraVenous Anesthesia (TIVA) or Spinal-block Anesthesia in a randomized manner\n* No contraindication to either TIVA or spinal anesthesia\n\nExclusion Criteria:\n\n* Age \\\u003C18 years.\n* Patients undergoing revision TKA or procedures other than elective primary TKA.\n* Ineligibility for same-day discharge as determined by the surgical or anesthesia team.\n* Contraindications to either anesthetic technique (e.g., spinal block anesthesia contraindicated due to coagulopathy, infection at puncture site, or patient refusal).\n* Known allergy or hypersensitivity to study-related medications.\n* Significant pre-existing cognitive impairment or dementia that would preclude valid participation in Short Portable Mental Status Questionnaire (SPMSQ), and 3-Minute Diagnostic Assessment for Confusion Assessment Method (3D-CAM) assessments.\n* Severe chronic pain syndromes (e.g., fibromyalgia, centrally mediated pain disorders) that could confound perioperative pain assessment.\n* Body mass index (BMI) \\> 40.\n* Prisoners or other vulnerable populations unable to provide voluntary consent.\n* Unable to give appropriate consent or difficult to comprehend and complete cognitive assessment surveys and questionnaires",{"count":134,"type":21},150,[114,136],"PHASE2","The purpose of this study is to compare same-day discharge rates and recovery outcomes across an adult patient population undergoing elective Total Knee Arthroplasty (TKA), and randomized to receive either spinal block anesthesia or Total IntraVenous Anesthesia (TIVA).\n\nPrimary Aim: assess same-day discharge rates between study arms (TIVA vs spinal).\n\nSecondary Aim: Postoperative comparison of recovery during PostOperative Anesthesia Care Unit (PACU) admission, diagnostic assessment scores; outcomes related to cognition, hemodynamic stability, pain, nausea and vomiting; analysis of IntraOperative electroencephalogram (EEG) monitoring metrics, e.g., total suppression time, average Bi-spectral Index monitor (BIS) value, Spectral Edge Frequency (SEF); ability for Physical Therapy (PT) evaluation prior to discharge; longterm-followup (LTFU), hospital readmission, return to surgery, etc.; adverse event (AE) monitoring.",[139],"Total Knee Arthroplasty (TKA)",[141,142,143,144],"Total IntraVenous Anesthesia (TIVA)","Spinal block","Delirium - Postoperative","Postoperative Recovery","2026-06-23",{"date":147,"type":34},"2026-06-26",{"date":149,"type":34},"2026-03-11",{"date":151,"type":21},"2028-06",{"name":40,"class":41},1,{"id":155,"slug":156,"hasResults":12,"nctId":157,"briefTitle":158,"officialTitle":158,"acronym":159,"eligibilityCriteria":160,"healthyVolunteers":161,"sex":16,"minAge":17,"maxAge":162,"enrollmentInfo":163,"targetDuration":4,"studyType":22,"phases":165,"briefSummary":166,"conditions":167,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":171,"lastUpdatePostDateStruct":172,"startDateStruct":173,"completionDateStruct":175,"leadSponsor":177,"locationsCount":153},"100644304","phase-1-effects-of-stimulant-medications-in-ptsd-100644304","NCT07664631","Effects of Stimulant Medications in PTSD","SMP","Inclusion Criteria:\n\n* Age 18 - 65 years old\n* BMI 19-30 kg\u002Fm2\n* English fluency\n\nExclusion Criteria:\n\n* Individuals with current moderate or severe substance use disorder, no past stimulant or cocaine use disorder\n* Individuals with current acute or high risk of suicide or suicide attempt in past 6 months\n* Individuals with current psychotic or bipolar disorder\n* Individuals with past schizophrenia, schizoaffective disorder, psychotic bipolar disorder, stimulant or cocaine use disorder\n* Individuals with chronic (non-PRN) treatment with antipsychotic drug (except PRN quetiapine 25mg PO qHS) or D2 antagonist\n* Individuals with medications with significant PD or PK interactions\n* Individuals with current treatment with a stimulant medication\n* Individuals with court or legally mandated treatment\n* Individuals with unstable or untreated medical disorder that would increase the risk of serious side effects of study drug (unstable hypertension, tachycardia, cardiac arrhythmia, recent MI or stroke, clinically significant neuropsychiatric or neurological disorder)\n* Members of a vulnerable population\n* High blood pressure (\\>140\u002F90)\n* Women who are pregnant, breastfeeding, or planning to become pregnant",true,"65 Years",{"count":164,"type":21},40,[114],"While there have been advances in understanding post-traumatic stress disorder (PTSD) as a disorder and its biological features, unfortunately only one out of five traumatized persons with PTSD reach remission after cycling through evidence-based and\u002For FDA-approved medications. This is especially unfortunate given that people with PTSD are often from vulnerable populations, or those whose professions entail personal sacrifice. It is clear that new serotonergic antidepressants and atypical antipsychotics will not be sufficient to fix this gap, and new mechanisms of action need to be tested. In the current proposal, the investigators test the hypothesis that mixed amphetamine salts (brand name Adderall), FDA-approved for treating attention deficit hyperactivity disorder (ADHD), can improve PTSD outcomes.",[168,169,170],"Adderall","PTSD","Post Traumatic Stress Disorder","2026-06-18",{"date":119,"type":34},{"date":174,"type":21},"2026-09-15",{"date":176,"type":21},"2027-09-15",{"name":40,"class":41},{"id":179,"slug":180,"hasResults":12,"nctId":181,"briefTitle":182,"officialTitle":183,"acronym":184,"eligibilityCriteria":185,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":186,"targetDuration":4,"studyType":22,"phases":188,"briefSummary":189,"conditions":190,"keywords":193,"overallStatus":96,"whyStopped":4,"lastUpdateSubmitDate":197,"lastUpdatePostDateStruct":198,"startDateStruct":200,"completionDateStruct":202,"leadSponsor":204,"locationsCount":153},"100642335","phase-2-a-study-evaluating-the-combination-of-immunotherapy-with-radiotherapy-in-non-small-cell-lung-cancer-100642335","NCT07603856","A Study Evaluating The Combination of Immunotherapy With Radiotherapy in Non-Small Cell Lung Cancer","A Randomized Phase II Study of Radiotherapy Plus Immune Checkpoint Inhibitor Therapy Versus Standard of Care Chemotherapy in Patients With Metastatic or Relapsed Non-Small Cell Lung Cancer Previously Treated With Immunotherapy","REVIVE","Inclusion Criteria:\n\n* Disease-Related Criteria\n\n  * Patients must have histologically or cytologically confirmed metastatic or recurrent non-small cell lung cancer (NSCLC) with progression on prior immunotherapy\n  * The patient's disease is eligible for SOC treatment with immunotherapy or chemotherapy.\n  * Patients must have measurable disease per RECIST v1.1, defined as at least one lesion that can be accurately measured in at least one dimension with longest diameter ≥10 mm (or ≥15 mm short axis for lymph nodes) by CT or MRI\n  * Patients must have at least one lesion that meets criteria for hypofractionated ablative RT treatment:\n  * Tumor volume 0.25 cc to 65 cc (approximately ≤5 cm maximal dimension)\n  * Located in sites amenable to ablative RT (see radiotherapy section for specific anatomic criteria)\n  * Note: Tumors \\>65 cc may be partially treated to 65 cc volume\n  * Prior\u002FConcurrent Therapy Criteria\n  * Patients must have received exactly ONE prior line of anti-PD-1 or anti-PD-L1 therapy for non-small cell lung cancer. This therapy may have been given as:\n  * Monotherapy\n  * In combination with chemotherapy\n  * In combination with another immunotherapy such as CTLA-4 inhibition\n  * In combination with a targeted therapy, such as adagrasib\n  * Special Cases for Neoadjuvant\u002FAdjuvant Immunotherapy:\n  * If patient received neoadjuvant, adjuvant, or consolidation anti-PD-1\u002FPD-L1 therapy for Stage I-III disease and progressed ≤365 days from initiation (Cycle 1 Day 1), this counts as the single allowed therapy for advanced disease\n  * If patient progressed \\>365 days from neoadjuvant\u002Fadjuvant therapy initiation, this does NOT count as therapy for advanced disease, and patient must have received subsequent anti-PD-1\u002FPD-L1 therapy for Stage IV or recurrent disease\n  * Patients with the following sensitizing mutations are ineligible, given known poor response to immunotherapy: EGFR, ALK, ROS1, RET, NTRK, HER2.\n  * Patients with the following sensitizing mutations must have previously received at least one of the appropriate targeted therapies, in addition to prior immunotherapy: BRAF, KRAS, MET. Prior targeted therapy for participants with targetable alterations is allowed if all other eligibility criteria is also met.\n* Clinical\u002FLaboratory Criteria\n\n  * Age ≥18 years\n  * ECOG Performance Status 0-2 (see Appendix A)\n  * Participants must be able to safely receive the investigational drug combination and the investigator's choice of standard of care regimens described in Section 5.1 (Agent Administration), per the current FDA-approved package inserts, treating investigator's discretion, and institutional guidelines.\n  * Patients with new or progressive brain metastases (active brain metastases) or leptomeningeal disease are eligible if the treating physician determines that immediate CNS specific treatment is not required and is unlikely to be required during the first cycle of therapy.\n  * Patients with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial.\n  * Because radiation and chemotherapy are known to be teratogenic, women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation. Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately. Both men and women treated or enrolled on this protocol must also agree to use adequate contraception prior to the study, for the duration of study participation, and 3 months after completion of immunotherapy, radiation, and\u002For chemotherapy administration.\n  * Ability to understand and the willingness to sign a written informed consent document.\n\nExclusion Criteria:\n\n* Patients with history of (non-infectious) pneumonitis requiring corticosteroids.\n* Patients with evidence of interstitial lung disease.\n* Patients with uncontrolled intercurrent illness.\n* Pregnant women are excluded from this study. Radiation is considered Class X and chemotherapy such as docetaxel are considered Class D agents with the potential for teratogenic or abortifacient effects. Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with radiation, immunotherapy, and chemotherapy breastfeeding should be discontinued if the mother is participating in the study.\n\nRadiation-Specific Exclusions\n\n* Patients who have received prior radiation to any of the planned treatment sites (\\>10% dose overlap)\n* Patients with lesions in locations not amenable to safe ablative RT delivery, including:\n* Esophagus or stomach directly involved by tumor (unless dose constraints can be met)\n* Small bowel or colon directly involved by tumor (unless dose constraints can be met)\n* Spinal cord lesions with \\\u003C3 mm clearance between epidural disease and spinal cord",{"count":187,"type":21},39,[136],"Current clinical trials testing the combination of immunotherapy with radiotherapy.",[191,192],"Non-Small Cell Lung Cancer","Metastatic Lung Cancer",[194,195,196],"Radiotherapy","Chemotherapy","Immunotherapy","2026-06-12",{"date":199,"type":34},"2026-06-16",{"date":201,"type":21},"2026-12-12",{"date":203,"type":21},"2030-06-25",{"name":40,"class":41},{"id":206,"slug":207,"hasResults":12,"nctId":208,"briefTitle":209,"officialTitle":210,"acronym":211,"eligibilityCriteria":212,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":213,"targetDuration":4,"studyType":22,"phases":215,"briefSummary":216,"conditions":217,"keywords":4,"overallStatus":96,"whyStopped":4,"lastUpdateSubmitDate":197,"lastUpdatePostDateStruct":219,"startDateStruct":220,"completionDateStruct":222,"leadSponsor":224,"locationsCount":153},"100620167","phase-1-lactulose-to-improve-gut-health-in-cancer-patients-receiving-immunotherapy-100620167","NCT07354100","Lactulose to Improve Gut Health in Cancer Patients Receiving Immunotherapy","Bifidobacterium Lactulose Optimization in Oncology and Microbiome (BLOOM)","(BLOOM)","Inclusion Criteria:\n\n* Inclusion Criteria Phase I\n* Patients must have a histologically confirmed malignancy that is to receive exclusively ICIs (no chemotherapy or RT in combination) per standard of care during the time in which lactulose will be administered. This includes, but is not limited to, melanoma, cutaneous squamous cell carcinoma, non-small cell lung cancer, mesothelioma, head and neck squamous cell carcinoma, classical Hodgkin lymphoma, primary mediastinal large B-cell lymphoma, urothelial cancer, MSI\u002FMMRd cancer, cancers with high tumor mutational burden (\\>=10 muts\u002FmB), esophageal cancer, hepatocellular carcinoma, and renal cell carcinoma. Anti-PD-1 or anti-PD-L-1 therapy combinations with anti-LAG-3 or anti-CTLA-4 combinations are permitted.\n* Age ≥18 years. Because no dosing or adverse event data are currently available on the use of lactulose in combination with ICIs in patients \\\u003C18 years of age, children are excluded from this study.\n* ECOG performance status ≤2 (Karnofsky ≥60%, see Appendix A).\n* Patients must be able to ingest liquids.\n* Inclusion Criteria Phase II\n* Patients must have a histologically confirmed cutaneous or mucosal melanoma. Uveal melanoma is excluded.\n* Measurable disease per RECIST 1.1.32\n* Documented primary or acquired resistance to anti-PD-1 and anti-CTLA4 therapy per SITC guidelines.21 Primary resistance is defined as disease progression after a minimum of 6 weeks of therapy, provided the patient has received at least two full cycles of treatment, and there has been no prior evidence of clinical benefit (partial response, complete response, or stable disease lasting at least 6 months). Acquired resistance is defined as disease progression after an initial clinical benefit while still on therapy or within 12 weeks of discontinuing therapy, provided the patient received at least two cycles and 6 weeks of therapy.\n* Patients with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial.\n* Planned to receive standard ICI therapy (no RT\u002FICI or chemotherapy\u002FICI combinations).\n* Age ≥18 years. Because no dosing or adverse event data are currently available on the use of lactulose in combination with ICIs in patients \\\u003C18 years of age, children are excluded from this study.\n* ECOG performance status ≤2 (Karnofsky ≥60%, see Appendix A).\n* Patients must be able to ingest liquids.\n\nExclusion Criteria:\n\n* Exclusion Criteria for Phase I\n* History of allergic reactions attributed to compounds of similar chemical or biologic composition to ICIs or lactulose.\n* Current serious concomitant illnesses include cardiovascular diseases (such as uncontrolled congestive heart failure, hypertension, cardiac ischemia, myocardial infarction, and severe cardiac arrhythmias), bleeding disorders, autoimmune diseases, severe obstructive or restrictive pulmonary diseases, active systemic infections, and inflammatory bowel disorders, including HIV or AIDS-related illnesses or active hepatitis B or C virus.\n* The ongoing use of systemic antibiotics or the previous use of antibiotics in the 2 weeks before enrollment.\n* Presence of a chronic intestinal disease (for example, celiac, or malabsorption) where the frequency of bowel movements would interfere with study assessments.\n* Absence of the large bowel.\n* The presence of absolute contraindications to lactulose administration includes galactosemia or other conditions that necessitate a low intake of galactose.\n* Expected to require any other form of systemic anti-neoplastic therapy while in the study (i.e., chemotherapy or radiation therapy).\n* Symptomatic CNS metastases and\u002For leptomeningeal involvement. Patients with CNS metastases and\u002For leptomeningeal involvement may participate if they are clinically stable, as judged by the enrolling investigator.\n* Has an active autoimmune disease or a documented history of autoimmune disease or syndrome that requires systemic steroids or immunosuppressive agents. Patients with vitiligo, type I diabetes, or resolved childhood asthma\u002Fatopy are exceptions to this rule.\n* A history of immune-related adverse events to ICIs that precludes the investigator from comfortably re-challenging with ICIs.\n* Has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial.\n* Exclusion Criteria for Phase II\n* Patients with a \"currently active\" second malignancy other than non-melanoma skin cancers. Patients are not considered to have a \"currently active\" malignancy if they have completed therapy and are free of disease for ≥ 2 years.\n* History of allergic reactions attributed to compounds of similar chemical or biologic composition to ICIs or lactulose.\n* Current serious concomitant illnesses include cardiovascular diseases (such as uncontrolled congestive heart failure, hypertension, cardiac ischemia, myocardial infarction, and severe cardiac arrhythmias), bleeding disorders, autoimmune diseases, severe obstructive or restrictive pulmonary diseases, active systemic infections, and inflammatory bowel disorders, including HIV or AIDS-related illnesses or active hepatitis B or C virus.\n* The ongoing use of systemic antibiotics or the previous use of antibiotics in the 2 weeks before enrollment.\n* Presence of a chronic intestinal disease (for example, celiac, or malabsorption) where the frequency of bowel movements would interfere with study assessments.\n* Absence of the large bowel\n* The presence of absolute contraindications to lactulose administration includes galactosemia or other conditions that necessitate a low intake of galactose.\n* Expected to require any other form of systemic anti-neoplastic therapy while in the study (i.e., chemotherapy or radiation therapy).\n* Symptomatic CNS metastases and\u002For leptomeningeal involvement. Patients with CNS metastases and\u002For leptomeningeal involvement may participate if they are clinically stable, as judged by the enrolling investigator.\n* Has an active autoimmune disease or a documented history of autoimmune disease or syndrome that requires systemic steroids or immunosuppressive agents. Patients with vitiligo, type I diabetes, or resolved childhood asthma\u002Fatopy are exceptions to this rule.\n* A history of immune-related adverse events to ICIs that precludes the investigator from comfortably re-challenging with ICIs.\n* Has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial.",{"count":214,"type":21},55,[114,136],"The purpose of this study is to see if lactulose can improve the effectiveness of immunotherapy in patients with advanced cancer.",[218],"Cancer",{"date":199,"type":34},{"date":221,"type":21},"2026-12-15",{"date":223,"type":21},"2029-04-13",{"name":40,"class":41},{"id":226,"slug":227,"hasResults":12,"nctId":228,"briefTitle":229,"officialTitle":230,"acronym":4,"eligibilityCriteria":231,"healthyVolunteers":12,"sex":16,"minAge":232,"maxAge":110,"enrollmentInfo":233,"targetDuration":4,"studyType":22,"phases":235,"briefSummary":236,"conditions":237,"keywords":238,"overallStatus":96,"whyStopped":4,"lastUpdateSubmitDate":197,"lastUpdatePostDateStruct":240,"startDateStruct":242,"completionDateStruct":243,"leadSponsor":245,"locationsCount":153},"100550406","using-text-messages-to-improve-oral-chemotherapy-for-adolescents-and-adults-with-acute-lymphoblastic-leukemia-100550406","NCT06446661","Using Text Messages to Improve Oral Chemotherapy for Adolescents and Adults With Acute Lymphoblastic Leukemia","Improving Oral Chemotherapy Adherence in Maintenance for Adolescents and Adults With Acute Lymphoblastic Leukemia Using Text Messages","Inclusion Criteria:\n\n* Age of 15-39 years-old at the time of initial ALL diagnosis\n* Diagnosed with ALL\n* Currently receiving treatment with pediatric-based regimen that includes maintenance with mercaptopurine and methotrexate (e.g., CALGB 10403). Study participation begins with the start of maintenance, so enrollment occurs prior to the start of maintenance.\n\nExclusion Criteria:\n\n* Patient or caregiver who would receive text message reminders does not have a cell phone that receives text messages\n* Patient does not wish to participate\n* Text messages will be crafted in the patient's preferred language for medical communication, so English fluency is not an enrollment requirement.","15 Years",{"count":234,"type":21},38,[24],"The purpose of this section is to learn how text message reminders might help with regularly taking chemotherapy medications for Adolescents and Adults with Acute Lymphoblastic leukemia (ALL).",[117],[239],"Oral Chemotherapy",{"date":241,"type":34},"2026-06-15",{"date":221,"type":21},{"date":244,"type":21},"2028-06-15",{"name":40,"class":41},{"id":247,"slug":248,"hasResults":12,"nctId":249,"briefTitle":250,"officialTitle":251,"acronym":4,"eligibilityCriteria":252,"healthyVolunteers":12,"sex":253,"minAge":17,"maxAge":4,"enrollmentInfo":254,"targetDuration":4,"studyType":22,"phases":256,"briefSummary":257,"conditions":258,"keywords":4,"overallStatus":96,"whyStopped":4,"lastUpdateSubmitDate":197,"lastUpdatePostDateStruct":260,"startDateStruct":261,"completionDateStruct":263,"leadSponsor":265,"locationsCount":153},"100499973","phase-2-prostate-cancer-treatment-using-androgen-deprivation-therapy-and-focal-prostate-ablation-100499973","NCT05790213","Prostate Cancer Treatment Using Androgen Deprivation Therapy and Focal Prostate Ablation","Phase II Trial of Focal Prostate Ablation Combined With Androgen Deprivation Therapy for Prostate Cancer Treatment","Inclusion Criteria:\n\n* Subjects must have intermediate-risk PCa as defined by the below criteria:\n\n  a. Favorable intermediate-risk PCa: i. ≤ clinical stage T2c, GG2, and PSA ≤ 10 ng\u002FmL, and \\\u003C50% positive biopsy cores with PCa b. Unfavorable intermediate-risk PCa: i. ≤ clinical stageT2c, GG2, and PSA 10-20 ng\u002FmL, or ≥50% positive biopsy cores with PCa, or ii. ≤ clinical stage T2c, GG3, and PSA \\\u003C 20 ng\u002FmL\n* No mpMRI evidence of extra-prostatic extension (EPE) or seminal vesicle invasion, and if seminal vesical invasion is suspected, it must be excluded by prostate biopsy.\n* Subjects must have chosen to get Focal Therapy for the treatment of prostate cancer.\n* Subjects must have confirmed non-metastatic PCa following SOC screening for patients with unfavorable intermediate-risk PCa, a combination of computed tomography imaging of the abdomen and pelvis (CTAP) and technetium-99-mDP nuclear medicine bone scan (BS) and\u002For prostate-specific membrane antigen positron emission tomography (PSMA\u002FPET) scan prior to enrollment. The imaging studies should be obtained within 6-months of enrollment. Additional imaging is not required for men with favorable intermediate-risk PCa.\n* Subject must be male ≥ 18 years-old.\n* Subjects must have a life expectancy of at least 10-years per the opinion of the treating investigator.\n* Subjects must be designated as Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2 or Karnofsky Performance Status Scale Score ≥ 60%, see Appendix A).\n* Subjects must be fit to undergo general anesthesia and the FT surgical procedure, which includes adequate visualization of the prostate gland on transrectal ultrasound imaging, access to the urethra, perineum and rectum, as well as be tolerant of lithotomy positioning in the opinion of the treating investigator or the operating surgeon(s) if not the same as the treating investigator.\n* Subjects must have adequate organ and marrow function as defined below:\n\nHemoglobin ≥ 10 g\u002FdL Leukocytes ≥ 3,000\u002FmcL Absolute neutrophil count ≥ 1,500\u002FmcL Platelets ≥ 100,000\u002FmcL Total bilirubin ≤ 1.5 x institutional upper limit of normal (ULN) AST(SGOT)\u002FALT(SGPT) ≤ 2.5 × institutional ULN Creatinine \\\u003C 1.5 institutional ULN OR Calculated or measured creatinine clearance \\> 50 mL\u002Fmin\u002F1.73 m2 eGFR \\>30 mL\u002Fmin using the MDRD (modification of diet and renal disease) formula Serum albumin ≥3.0 g\u002FdL Serum potassium ≥3.5 mmol\u002FL\n\n* Subjects with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial.\n* Subjects who are sexually active with a woman of childbearing potential must agree to use a condom with spermicidal foam\u002Fgel\u002Ffilm\u002Fcream\u002Fsuppository and his partner must also be practicing a highly effective method of contraception (i.e., established use of oral, injected or implanted hormonal methods of contraception; placement of an intrauterine device or intrauterine system) during treatment and for 3-months following the last ADT treatment.\n* Ability to understand and the willingness to sign a written informed consent document.\n\nExclusion Criteria:\n\n* Subject has had prior or current PCa therapies, such as biologic, chemotherapy, hormone therapy, radiotherapy or surgery for PCa. Subjects may not have had undergone pelvic radiation, chemotherapy or immunotherapy treatment for a separate hematologic or visceral malignancy within 6-months of enrollment in the present study.\n* Subjects with locally advanced, nodal or metastatic prostate cancer.\n* Subjects who are unfit for pelvic mpMRI scanning (e.g., severe claustrophobia, permanent cardiac pacemaker, metallic implants that are likely to contribute to significant image artifacts, allergy or contraindication to gadolinium contrast agent.\n* History of allergy or intolerance to study drug components.\n* History of bilateral orchiectomy.\n* If the subject has an uncontrolled or major debilitating inter-current illness.\n* Subjects who are receiving any other investigational agents, or who have received other investigational agents in the past and who are no longer receiving these investigational agents may be eligible at the discretion of the principal investigator (PI).\n* Judgment by the treating investigator or PI that the subject is unsuitable to participate in the study and the subject is unlikely to comply with study procedures, restrictions and requirements.","MALE",{"count":255,"type":21},57,[136],"The purpose of this research is to gather information on the safety and effectiveness of combining focal prostate ablation therapy ((aka Focal Therapy, a surgical procedure) and androgen deprivation therapy (hormone therapy).",[259],"Prostate Cancer",{"date":199,"type":34},{"date":262,"type":34},"2025-05-05",{"date":264,"type":21},"2028-12-18",{"name":40,"class":41},{"id":267,"slug":268,"hasResults":12,"nctId":269,"briefTitle":270,"officialTitle":270,"acronym":271,"eligibilityCriteria":272,"healthyVolunteers":12,"sex":16,"minAge":273,"maxAge":4,"enrollmentInfo":274,"targetDuration":276,"studyType":54,"phases":4,"briefSummary":277,"conditions":278,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":283,"lastUpdatePostDateStruct":284,"startDateStruct":286,"completionDateStruct":288,"leadSponsor":290,"locationsCount":153},"100643795","bridge-us-bridging-readiness-in-deployed-neurotrauma-gaps-for-excellence-100643795","NCT07636213","BRIDGE-US: Bridging Readiness in Deployed Neurotrauma Gaps for Excellence","BRIDGE-US","Inclusion Criteria:\n\n1. Age: Subjects aged 16 years and older\n2. Injury Type\u002FEvidence: Patients with a confirmed PBI as demonstrated by head imaging or physical exam (evidence of dural penetration by a projectile)\n3. Timeframe: Patients must be enrolled within 8 hours of injury\n\nExclusion Criteria:\n\nNo subjects will be excluded based on gender or ethnicity for this study. Subjects under the age of 16 will be excluded. These subjects differ significantly in terms of neurodevelopment, physiology, and trauma response, which introduces heterogeneity that could confound study results. Additionally, pediatric PBI has distinct etiologies, treatment pathways, and prognostic indicators compared to adult PBI (note that age 16 and up are treated medically as adults).\n\nFULL EXCLUSION CRITERIA:\n\n1. Dead on Arrival (DOA): Patients who receive CPR with no return of pulse\n2. Non-penetrating injury: Patients with head injuries that do not include dural penetration\n3. Polytrauma: Patients with penetrating or blunt injuries to other parts of the body\n4. Known or suspected pregnancy\n5. Known or suspected prisoner","16 Years",{"count":275,"type":21},270,"7 Days","The purpose of this research study is to prospectively collect biospecimens, imaging, and clinical data from patients with penetrating brain injuries across high-volume PBI sites in the US (including UChicago). Biospecimens will undergo biomarker analysis - biomarker data specific to PBI is extremely limited, and could provide critical insight to outcome identification and clinical decision making.\n\nThis data will be used to build the first comprehensive PBI Data Commons, biorepository, and imaging repository which will create the infrastructure necessary to close critical knowledge gaps, advance biomarker discovery specific to PBI, and provide the foundation for future research aimed at improving prognostication and treatment for patients with this devastating injury.",[279,280,281,282],"Brain Injuries, Acute","Brain Trauma","Penetrating Head Injury","Traumatic Brain Injury","2026-06-08",{"date":285,"type":34},"2026-06-09",{"date":287,"type":21},"2026-07-01",{"date":289,"type":21},"2035-12-31",{"name":40,"class":41},{"id":292,"slug":293,"hasResults":12,"nctId":294,"briefTitle":295,"officialTitle":296,"acronym":4,"eligibilityCriteria":297,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":298,"enrollmentInfo":299,"targetDuration":4,"studyType":22,"phases":301,"briefSummary":302,"conditions":303,"keywords":309,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":283,"lastUpdatePostDateStruct":312,"startDateStruct":314,"completionDateStruct":316,"leadSponsor":318,"locationsCount":4},"100614682","phase-2-semaglutide-wegovy-treatment-for-trichotillomania-100614682","NCT07282769","Semaglutide (Wegovy) Treatment for Trichotillomania","Once Weekly Semaglutide Treatment of Trichotillomania: An Open-Label Study","Inclusion Criteria:\n\n1. Men and women age 18-75;\n2. Diagnosis of current trichotillomania based on DSM-5 criteria and confirmed using the clinician-administered MIDI (13);\n3. Hair pulling daily with urges to pull as the trigger in \\>50% of the episodes of pulling;\n4. Women of childbearing age are required to have a negative result on a beta-human chorionic gonadotropin pregnancy test;\n5. Women of childbearing potential utilizing a medically accepted form of contraception defined as double barrier, oral contraceptive, injectable contraceptive, implantable contraceptive devices, and abstinence\n\nExclusion Criteria:\n\n1. Infrequent pulling (i.e. less than daily) or automatic pulling (i.e. no urges to pull);\n2. Unstable medical illness or clinically significant abnormalities on laboratory tests, EKG, or physical examination at screen as determined by the investigator;\n3. History of seizures;\n4. Myocardial infarction within 6 months;\n5. Current pregnancy or lactation, or inadequate contraception in women of childbearing potential;\n6. A need for medication other than semaglutide with possible psychotropic effects or unfavorable interactions as determined by the investigator;\n7. Clinically significant suicidality (defined by the Columbia Suicide-Severity Rating Scale);\n8. Lifetime history of bipolar disorder type I or II, schizophrenia, or any psychotic disorder;\n9. Current skin picking disorder;\n10. Initiation of psychotherapy or behavior therapy within 3 months prior to study baseline;\n11. Initiation of psychotropic medications within 3 months prior to study baseline (stable doses will be allowed);\n12. Previous treatment with semaglutide;\n13. Use of any weight loss medications;\n14. Body mass index (BMI, calculated as weight in kilograms divided by height in meters squared) less than 23;\n15. Past-year substance use disorder other than tobacco use disorder or mild cannabis use disorder;\n16. Recent (30-day) use of illicit drugs except cannabis;\n17. History of diabetes, and current medical or neurological illness precluding participation based on physician judgment;\n18. Personal or family history of medullary thyroid cancer or multiple endocrine neoplasia 2A or 2B;\n19. History of pancreatitis.","75 Years",{"count":300,"type":21},10,[136],"This research study is testing the effectiveness and safety of semaglutide (Wegovy) in people with trichotillomania, also known as hair-pulling disorder.",[304,305,306,307,308],"Trichotillomania (Hair-Pulling Disorder)","Trichotillomania","Hair Pulling Disorder","Hair Pulling","Hair-Pulling Disorder",[310,311],"trichotillomania","hair pulling",{"date":313,"type":34},"2026-06-10",{"date":315,"type":21},"2026-06",{"date":317,"type":21},"2027-02",{"name":40,"class":41},{"id":320,"slug":321,"hasResults":12,"nctId":322,"briefTitle":323,"officialTitle":324,"acronym":4,"eligibilityCriteria":325,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":162,"enrollmentInfo":326,"targetDuration":4,"studyType":22,"phases":328,"briefSummary":329,"conditions":330,"keywords":332,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":283,"lastUpdatePostDateStruct":334,"startDateStruct":335,"completionDateStruct":336,"leadSponsor":338,"locationsCount":4},"100601553","phase-2-valbenazine-in-obsessive-compulsive-disorder-100601553","NCT07111988","Valbenazine in Obsessive Compulsive Disorder","Valbenazine in Obsessive-compulsive Disorder: A Randomized Double-blind Placebo-controlled Crossover Trial","Inclusion Criteria:\n\n1. Men and women aged 18-65 years\n2. Primary diagnosis of obsessive compulsive disorder (OCD)\n3. Yale Brown Obsessive Compulsive Scale (Y-BOCS) score of at least 21 at baseline (moderate or higher severity)\n4. Ability to understand and sign the consent form\n\nExclusion Criteria:\n\n1. Unstable medical illness based on history or clinically significant abnormalities on baseline physical examination\n2. Current pregnancy or lactation, or inadequate contraception in women of childbearing potential\n3. Subjects considered an immediate suicide risk based on the Columbia Suicide Severity Rating Scale (C-SSRS) (www.cssrs.columbia.edu\u002Fdocs)\n4. History of psychosis or bipolar disorder based on DSM-5 criteria\n5. Alcohol\u002Fsubstance use disorder and\u002For illegal substance use based on urine toxicology\n6. Initiation of psychological interventions within 3 months of screening (those who are continuing with CBT will be included)\n7. Use of any new psychotropic medication within 3 months of study entry (stable doses of psychotropics will be allowed)\n8. Major cognitive impairment that interferes with the capacity to understand and self-administer medication or provide written informed consent\n9. Abnormal liver function tests at baseline (greater than 2x the upper limit of normal)",{"count":327,"type":21},30,[136],"The primary aim of the study is to examine the efficacy and safety of valbenazine in adults with moderate to severe obsessive-compulsive disorder (OCD).",[331],"Obsessive-Compulsive Disorder",[333],"OCD",{"date":313,"type":34},{"date":315,"type":21},{"date":337,"type":21},"2027-12",{"name":40,"class":41},{"id":340,"slug":341,"hasResults":12,"nctId":342,"briefTitle":343,"officialTitle":343,"acronym":4,"eligibilityCriteria":344,"healthyVolunteers":12,"sex":50,"minAge":17,"maxAge":4,"enrollmentInfo":345,"targetDuration":4,"studyType":22,"phases":347,"briefSummary":348,"conditions":349,"keywords":351,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":283,"lastUpdatePostDateStruct":353,"startDateStruct":355,"completionDateStruct":357,"leadSponsor":359,"locationsCount":4},"100595577","continuous-glucose-monitoring-to-detect-postpartum-dysglycemia-in-patients-with-gestational-diabetes-100595577","NCT07034261","Continuous Glucose Monitoring to Detect Postpartum Dysglycemia in Patients With Gestational Diabetes","Inclusion Criteria:\n\n1. Age greater than or equal to 18\n2. Completed pregnancy with delivery of a live born infant(s). Pregnancies with multiple gestations will be included\n3. No prior history of type 1 or type 2 diabetes\n\n   \\* Patients with a history of gestational diabetes (GDM) in a prior pregnancy will be eligible for inclusion.\n4. GDM diagnosis by standard screening at 24-28 weeks\n\n   * 2 hour 75g oral glucose tolerance test (OGTT); one abnormal value required for diagnosis\n\n     * Fasting glucose 92\n     * 1 hour 180\n     * 2 hour 153\n   * 3 hour 100g OGTT - two abnormal values required for diagnosis\n\n     * Fasting glucose - 95\n     * 1 hour 180\n     * 2 hour 155\n     * 3 hour 140\n\nThere are no exclusion criteria for this study. Eligibility will be based on inclusion criteria.",{"count":346,"type":21},50,[24],"The aim of this study is to determine the ability of postpartum continuous glucose monitoring (CGM) for subjects with gestational diabetes (GDM) to predict dysglycemia on 4-12 week postpartum oral glucose tolerance test (OGTT).",[350],"Gestational Diabetes",[352],"CGM Device",{"date":354,"type":34},"2026-06-11",{"date":356,"type":21},"2026-09",{"date":358,"type":21},"2027-09",{"name":40,"class":41},{"id":361,"slug":362,"hasResults":12,"nctId":363,"briefTitle":364,"officialTitle":365,"acronym":4,"eligibilityCriteria":366,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":367,"targetDuration":4,"studyType":22,"phases":369,"briefSummary":370,"conditions":371,"keywords":4,"overallStatus":96,"whyStopped":4,"lastUpdateSubmitDate":283,"lastUpdatePostDateStruct":374,"startDateStruct":375,"completionDateStruct":377,"leadSponsor":379,"locationsCount":153},"100370724","phase-2-phase-ii-study-of-the-effects-of-laparoscopic-hyperthermic-intraperitoneal-chemotherapy-hipec-in-patients-with-advanced-gastric-cancer-100370724","NCT04107077","Phase II Study of the Effects of Laparoscopic Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Patients With Advanced Gastric Cancer","A Phase IIa Study of Laparoscopic Hyperthermic Intraperitoneal Chemotherapy (HIPEC) and PD-L1 Expression in Gastric Cancer With Peritoneal Metastases","Inclusion Criteria:\n\n* Patients with histologically confirmed GC\u002FPM only and\u002For positive peritoneal cytology, who have completed prior systemic chemotherapy for a minimum of 2 to 4 months duration.\n* Age ≥18 years. Because no dosing or adverse event data are currently available on the use of HIPEC for GC\u002FPM in patients under 18 years of age, children are excluded from this study, but will be eligible for future pediatric trials.\n* ECOG performance status ≤2 (Karnofsky ≥60%, see Appendix A).\n* Patients must have adequate organ and marrow function as defined below:\n\n  * leukocytes ≥3,000\u002FmcL\n  * absolute neutrophil count ≥1,500\u002FmcL\n  * platelets ≥100,000\u002FmcL\n  * total bilirubin ≤ institutional upper limit of normal (ULN)\n  * AST(SGOT)\u002FALT(SGPT) ≤3 × institutional ULN\n  * creatinine ≤ institutional ULN OR\n  * glomerular filtration rate (GFR) ≥50 mL\u002Fmin\u002F1.73 m2 unless data exists supporting safe use at lower kidney function values, no lower than 30 mL\u002Fmin\u002F1.73 m2 (see Appendix B).\n* Human immunodeficiency virus (HIV)-infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months are eligible for this trial.\n* For patients with evidence of chronic hepatitis B virus (HBV) infection, the HBV viral load must be undetectable on suppressive therapy, if indicated.\n* Patients with a history of hepatitis C virus (HCV) infection must have been treated and cured. For patients with HCV infection who are currently on treatment, they are eligible if they have an undetectable HCV viral load.\n* Patients with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial.\n* Patients with known history or current symptoms of cardiac disease, or history of treatment with cardiotoxic agents, should have a clinical risk assessment of cardiac function using the New York Heart Association Functional Classification. To be eligible for this trial, patients should be class 2B or better.\n* Expected survival greater than 3 months.\n* Because cisplatin and Mitomycin C are pregnancy category D and potentially teratogenic, women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation. Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately. Men treated or enrolled on this protocol must also agree to use adequate contraception prior to the study, for the duration of study participation, and 4 months after completion of the study.\n* Ability to understand and the willingness to sign a written informed consent document.\n\nExclusion Criteria:\n\n* Patients with coexistence of another untreated malignant neoplasm other than basal cell carcinoma of the skin within the last five years.\n* Sites of metastases other than loco-regional lymph nodes and peritoneum (ex. Visceral metastases such as liver, lungs, bone, brain).\n* Patients who have not recovered from adverse events due to prior anti-cancer therapy (i.e., have residual toxicities \\> Grade 1) with the exception of alopecia.\n* Patients who are receiving any other investigational agents.\n* History of allergic reactions attributed to compounds of similar chemical or biologic composition to cisplatin and Mitomycin C.\n* Patients with uncontrolled intercurrent illness.\n* Patients with psychiatric illness\u002Fsocial situations that would limit compliance with study requirements.\n* Pregnant women are excluded from this study because cisplatin and Mitomycin C are class D agents with the potential for teratogenic or abortifacient effects. Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with cisplatin and Mitomycin C, breastfeeding should be discontinued if the mother is treated with cisplatin and Mitomycin C.",{"count":368,"type":21},21,[136],"To assess if PD-L1 expression can be upregulated in peritoneal metastases from gastric cancer after the administration of HIPEC with greater frequency compared to systemic chemotherapy alone",[372,373],"Gastric Cancer","Peritoneal Carcinomatosis",{"date":354,"type":34},{"date":376,"type":34},"2025-09-09",{"date":378,"type":21},"2030-06-01",{"name":40,"class":41},{"id":381,"slug":382,"hasResults":12,"nctId":383,"briefTitle":384,"officialTitle":384,"acronym":4,"eligibilityCriteria":385,"healthyVolunteers":161,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":386,"targetDuration":4,"studyType":54,"phases":4,"briefSummary":388,"conditions":389,"keywords":394,"overallStatus":96,"whyStopped":4,"lastUpdateSubmitDate":398,"lastUpdatePostDateStruct":399,"startDateStruct":400,"completionDateStruct":402,"leadSponsor":404,"locationsCount":153},"100092968","a-study-of-the-natural-progression-of-interstitial-lung-disease-ild-100092968","NCT00470327","A Study of the Natural Progression of Interstitial Lung Disease (ILD)","Inclusion Criteria:\n\n* Interstitial lung disease\n\nExclusion Criteria:\n\n* Does not have Interstitial lung disease",{"count":387,"type":21},4000,"We propose to acquire data and blood samples on all patients being cared for by the Interstitial Lung Disease (ILD) program. Additionally, we will collect data and blood samples from a control group for comparator purposes. In doing so, we will be able to describe the \"phenotypic\" expression of these diseases.",[390,391,392,393],"Interstitial Lung Diseases","Idiopathic Pulmonary Fibrosis","Sarcoidosis","Connective Tissue Disorder",[395,396,392,397],"Interstitial lung diseases","idiopathic pulmonary fibrosis","mRNA and cytokine expression","2026-06-05",{"date":285,"type":34},{"date":401,"type":34},"2005-09",{"date":403,"type":21},"2030-12",{"name":40,"class":41},{"id":406,"slug":407,"hasResults":12,"nctId":408,"briefTitle":409,"officialTitle":409,"acronym":410,"eligibilityCriteria":411,"healthyVolunteers":12,"sex":16,"minAge":412,"maxAge":4,"enrollmentInfo":413,"targetDuration":4,"studyType":22,"phases":415,"briefSummary":416,"conditions":417,"keywords":421,"overallStatus":96,"whyStopped":4,"lastUpdateSubmitDate":429,"lastUpdatePostDateStruct":430,"startDateStruct":431,"completionDateStruct":433,"leadSponsor":435,"locationsCount":153},"100563640","recovery-legal-care-clinical-trial-100563640","NCT06618794","Recovery Legal Care Clinical Trial","HVIP-MLP","Inclusion Criteria:\n\n* Treatment for an interpersonal violent injury at the University of Chicago Trauma Center (e.g., gunshot, stab wound, assault)\n* Ages 14+ years\n* Able to provide informed consent (18 years and older) or assent (14-17 years)\n\nInclusion of women and minorities: This research proposal includes women and ethnic minorities. Patient participants will be primarily non-Hispanic Black or Hispanic race and ethnicity. The study expects participants to be proportional to the population-wide estimates for the South Side community. The majority will be low-income with variable functional health literacy. These characteristics are representative of the target population and describe the population most likely to benefit from the proposed study. Youth stakeholder participants will be multi-ethnic and racially diverse.\n\nInclusion of children: This study will include children ages 14-17 years old, based on Illinois state labor laws for child employment, as well as the ages of youth who are primarily treated for penetrating injury at the UCMC trauma center. This age is also a pragmatic cutoff for children providing meaningful input on community and healthcare solutions to violence.\n\nExclusion Criteria:\n\n* Diagnosis of severe mental illness (e.g., psychotic disorder, schizophrenia, suicidality)\n* Treated for a non-interpersonal violent injury type (e.g., car accident)\n* Treated for self-inflicted or accidental injuries\n* Unable to provide informed consent due to mental status\n* Prior receipt of legal services at UCMC within the past year\n* Currently imprisoned or incarcerated\n* Residing at a non-Illinois address\n* Non-English speakers","14 Years",{"count":414,"type":21},500,[24],"Hospital-Based Violence Intervention Programs (HVIPs) affiliated with trauma centers in the US often focus on individual behavior modification for reduction in re-victimization. There is a lack of reproducible evidence that has demonstrated effectiveness, given the exclusion of addressing inequities in the Social and Structural Determinants of Health (SSDOH), often the root causes of violent injury and preventable homicide. The study investigators created a Medical Legal Partnership (MLP) to partner with an existing HVIP. This novel program offers beside legal assistance to address the SSDOH. The purpose of this study is to evaluate the effectiveness of the HVIP-MLP program in improving perceived stress, violence-related outcomes, legal needs, health-related quality of life, and PTSD symptoms.",[418,419,420],"Firearm Injury","Economic Problems","Injury Traumatic",[422,423,424,425,426,427,428],"Firearm injury","Community violence","Medical-Legal Partnership","Structural violence","Civil law attorneys","Health-Harming Legal Needs","Hospital-Based Violence Intervention Program","2026-06-04",{"date":283,"type":34},{"date":432,"type":34},"2025-02-10",{"date":434,"type":21},"2027-08-31",{"name":40,"class":41},{"id":437,"slug":438,"hasResults":12,"nctId":439,"briefTitle":440,"officialTitle":441,"acronym":4,"eligibilityCriteria":442,"healthyVolunteers":12,"sex":50,"minAge":17,"maxAge":443,"enrollmentInfo":444,"targetDuration":4,"studyType":22,"phases":445,"briefSummary":446,"conditions":447,"keywords":4,"overallStatus":96,"whyStopped":4,"lastUpdateSubmitDate":449,"lastUpdatePostDateStruct":450,"startDateStruct":451,"completionDateStruct":453,"leadSponsor":455,"locationsCount":153},"100582808","aya-omgyes-sexual-health-study-100582808","NCT06868121","AYA OMGYES Sexual Health Study","Assessing the Impact of a Web-based Educational Program on the Sexual Health Outcomes of Young Adult Female Cancer Survivors ~ A Pilot Trial","Inclusion Criteria:\n\n* Age 18 to 45 years\n* Diagnosis of cancer between the ages of 15 and 45\n* Female genitalia, regardless of gender\n* Diagnosed with sexual dysfunction\n* Complete Remission and at least two months from a major treatment\n* Patients with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial\n* Ability to participate in study modules and to respond to surveys\n* Ability to understand and the willingness to sign a written informed consent document\n\nExclusion Criteria:\n\n* Patients receiving other investigational agents\n* Patients expected to be neutropenic or have a significantly high infection risk that would exclude them from vaginal penetration\n* Patients who are unable complete the study intervention or surveys","45 Years",{"count":327,"type":21},[24],"The purpose of this study is to assess the impact of the web-based intervention OMGYES.com on sexual dysfunction in young adult (YA) female-bodied cancer survivors. This pilot trial seeks to evaluate the intervention's:\n\n* feasibility\n* acceptability\n* appropriateness.\n\nResearchers will utilize an active observation period to compare outcomes between those receiving the intervention immediately and those who haven't\n\nParticipants will:\n\n* Complete online modules at home\n* Visit the clinic every 5 weeks for questionnaires",[448],"Sexual Dysfunction","2026-06-03",{"date":398,"type":34},{"date":452,"type":34},"2025-01-16",{"date":454,"type":21},"2026-11-01",{"name":40,"class":41},{"id":457,"slug":458,"hasResults":12,"nctId":459,"briefTitle":460,"officialTitle":461,"acronym":462,"eligibilityCriteria":463,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":464,"targetDuration":4,"studyType":22,"phases":466,"briefSummary":467,"conditions":468,"keywords":471,"overallStatus":96,"whyStopped":4,"lastUpdateSubmitDate":449,"lastUpdatePostDateStruct":473,"startDateStruct":474,"completionDateStruct":476,"leadSponsor":478,"locationsCount":153},"100584262","achieving-routine-intervention-and-screening-for-emotional-health-100584262","NCT06887049","Achieving Routine Intervention and Screening for Emotional Health","ARISE: Achieving Routine Intervention and Screening for Emotional Health: Randomized Controlled Trial","ARISE","Inclusion Criteria:\n\n* Patient at a participating clinic\n* Type 2 diabetes\n* Adult (18 years or older)\n* A1C \\> 8%\n\nExclusion Criteria:\n\n* Pregnant",{"count":465,"type":21},1250,[24],"The purpose of this project is to evaluate the effectiveness of diabetes distress screening and intervention on patients with type 2 diabetes mellitus (T2DM).",[469,470],"Type 2 Diabetes Mellitus (T2DM)","Diabetes Distress",[472],"diabetes distress screening",{"date":398,"type":34},{"date":475,"type":34},"2026-03-10",{"date":477,"type":21},"2028-09",{"name":40,"class":41},{"id":480,"slug":481,"hasResults":12,"nctId":482,"briefTitle":483,"officialTitle":484,"acronym":4,"eligibilityCriteria":485,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":486,"targetDuration":4,"studyType":22,"phases":487,"briefSummary":488,"conditions":489,"keywords":492,"overallStatus":96,"whyStopped":4,"lastUpdateSubmitDate":449,"lastUpdatePostDateStruct":494,"startDateStruct":495,"completionDateStruct":497,"leadSponsor":499,"locationsCount":153},"100419913","phase-2-study-of-chemotherapy-free-induction-regimen-for-ph-acute-lymphoblastic-leukemia-with-inotuzumab-ozogamicin-ino-100419913","NCT04747912","Study of Chemotherapy-Free Induction Regimen for Ph+ Acute Lymphoblastic Leukemia With Inotuzumab Ozogamicin (InO)","A Phase II Study of a Chemotherapy-Free Induction Regimen for Ph+ Acute Lymphoblastic Leukemia (ALL) Incorporating Inotuzumab Ozogamicin (InO)","Inclusion Criteria:\n\n1. Must be a newly diagnosed and untreated patient with Ph+ B-cell Acute Lymphoblastic Leukemia and CD22 expression on ≥20% of blasts.\n2. 18 years old or older.\n3. Bone marrow involvement with ≥20% lymphoblasts and demonstration of BCR-ABL1 via fluorescence in situ hybridization (FISH) studies or PCR-based testing. Patients with \\>1000\u002Fmm3 lymphoblasts in the peripheral blood that cannot undergo bone marrow biopsy and aspiration due to clinical condition are also eligible.\n4. Eastern Cooperative Oncology Group (ECOG) performance status 0-2.\n5. Adequate organ function as confirmed by clinical\u002Fmedical record.\n6. Patients must be at least 2 weeks from major surgery, radiation therapy, or participation in other investigational trials, and must have recovered from clinically significant toxicities related to these prior treatments.\n7. Patients must voluntarily sign and date an informed consent, approved by an Independent Ethics Committee\u002FInstitutional Review Board prior to starting any screening or study-specific procedures.\n8. Females of childbearing potential will use effective contraception during treatment with InO and for at least 8 months after the last dose. Males with female partners of reproductive potential will use effective contraception during treatment with Inotuzumab Ozogamicin and for at least 5 months after the last dose. A patient is of childbearing potential if, in the opinion of the treating investigator, he\u002Fshe is biologically capable of having children and is sexually active. Female patients who are not of childbearing potential (ie, meet at least one of the following criteria):\n\n   a. Have undergone hysterectomy or bilateral oophorectomy; or have medically confirmed ovarian failure; or are medically confirmed to be post-menopausal (cessation of regular menses for at least 12 consecutive months with no alternative pathological or physiological cause).\n9. Patients who are willing and able to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures.\n\nExclusion Criteria:\n\n1. Isolated extramedullary disease.\n2. Burkitt's or mixed-lineage leukemia.\n3. Active central nervous system (CNS) leukemia.\n4. Any prior therapy for ALL except for limited treatment (≤ 7 days) with corticosteroids or hydroxyurea and a single dose of intrathecal therapy. Patients who are being treated with chronic steroids for other reasons (eg, asthma, autoimmune disorders) are eligible.\n5. Current or chronic hepatitis B or C infection as evidenced by hepatitis B surface antigen and anti-hepatitis C antibody positivity, respectively, or known seropositivity for human immunodeficiency virus (HIV). HIV testing may need to be performed in accordance with local regulations or local practice. Patients with HIV but an undetectable viral load are eligible for enrollment\n6. Major surgery within ≤ 2 weeks before randomization.\n7. Unstable or severe uncontrolled medical condition (eg, unstable cardiac function or unstable pulmonary condition.\n8. Concurrent active malignancy other than non-melanoma skin cancer, carcinoma in situ of the cervix, or localized prostate cancer that has been definitely treated with radiation or surgery. Patients with previous malignancies are eligible provided that they have been disease free for ≥2 years or are not currently requiring treatment.\n9. Uncontrolled cardiac disease.\n10. QTcF \\> 500 msec (based on the average of 3 consecutive ECGs).\n11. History of chronic liver disease (eg, cirrhosis) or suspected alcohol abuse.\n12. History of hepatic veno-occlusive disease (VOD) or sinusoidal obstruction syndrome (SOS).\n13. Evidence of uncontrolled current serious active infection including sepsis, bacteremia, fungemia, or patients with a recent history (within 4 months) of deep tissue infections such as fasciitis or osteomyelitis.\n14. Medications known to predispose to Torsades de Pointes are prohibited throughout the treatment period of the study.\n15. Pregnant females; breastfeeding females; males with female partners of reproductive potential and females of childbearing potential not using highly effective contraception or not agreeing to continue highly effective contraception for a minimum of 5 months after the last dose of investigational product if male and 8 months after the last dose of investigational product if female.\n16. Patients who are investigational site staff members or relatives of those site staff members or patients who are Pfizer employees directly involved in the conduct of the trial.\n17. Participation in other investigational studies during active treatment phase.\n18. Other severe acute, chronic medical, psychiatric condition, or laboratory abnormality that may increase the risk associated with study participation or investigational product administration or may interfere with the interpretation of study results and, in the judgment of the Study Lead Principal Investigator, would make the patient inappropriate for entry into this study.",{"count":7,"type":21},[136],"This research study will add an anti-cancer drug (called inotuzumab ozogamicin also known as \"InO\") to treatment for participants with newly diagnosed Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL). Doctors leading this study hope to learn if adding InO to standard induction treatment for Ph+ ALL will lead to quicker, complete molecular remission (where the disease is not detectable even with very sensitive testing techniques). The purpose of this research is to gather information regarding the effectiveness of InO in newly-diagnosed Ph+ ALL patients that have not yet received treatment.",[490,117,491],"Lymphoblastic Leukemia","ph+ Acute Lymphoblastic Leukemia",[493,117,491],"leukemia",{"date":398,"type":34},{"date":496,"type":34},"2021-03-02",{"date":498,"type":21},"2028-03-01",{"name":40,"class":41},{"id":501,"slug":502,"hasResults":12,"nctId":503,"briefTitle":504,"officialTitle":505,"acronym":506,"eligibilityCriteria":507,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":508,"enrollmentInfo":509,"targetDuration":4,"studyType":22,"phases":511,"briefSummary":512,"conditions":513,"keywords":515,"overallStatus":96,"whyStopped":4,"lastUpdateSubmitDate":521,"lastUpdatePostDateStruct":522,"startDateStruct":524,"completionDateStruct":526,"leadSponsor":528,"locationsCount":153},"100530777","phase-2-communication-bridge-3-study-100530777","NCT06191198","Communication Bridge 3 Study","Communication Bridge: Optimizing an Evidence-based Intervention for Individuals With Primary Progressive Aphasia","CB3","Inclusion Criteria (person with PPA):\n\n1. Meets diagnostic criteria for PPA based on neurologist and supporting medical assessments (extracted from medical records)\n2. English as primary language used in daily communication activities (by self-report)\n3. Adequate hearing (aided or unaided) for communicating with others in a crowded room (by self-report)\n4. Adequate vision (aided or unaided) for reading a newspaper, or other functional materials (by self-report)\n5. Able to pass technology screening and demonstrates sufficient knowledge for use of video conference and Communication Bridge™ web application use (with or without training)\n6. Geriatric Depression Scale score ≤ 9\n7. Mild-moderate PPA informed by a structured interview with a speech-language pathologist and a standardized testing battery.\n\nInclusion Criteria (Co-enrolled communication partner):\n\n1. 18+ years of age\n2. English as primary language used in daily communication activities (by self-report)\n3. Adequate hearing (aided or unaided) for communicating with others in a crowded room (by self-report)\n4. Able to pass technology screening\\* and demonstrates sufficient knowledge for use of video conference and Communication Bridge™ web application use (with or without training)\n\nExclusion Criteria:\n\n* A dementia diagnosis other than Primary Progressive Aphasia\n* Participation is co-enrolled in an outside speech language therapy program during the study course.\n* Communication partners will be excluded if they have a pre-existing communication impairment that would affect study participation (e.g., aphasia, dementia)\n\nMedical records will be requested and reviewed to determine eligibility","100 Years",{"count":510,"type":21},200,[136],"This study will use a randomized controlled trial design to evaluate the effect of two evidence-based treatments for adults with mild-moderate Primary Progressive Aphasia (PPA). The aim of the study is to help us better understand the effects of speech-language therapy on communication abilities in individuals with PPA.",[514],"Primary Progressive Aphasia",[516,517,518,519,520],"Aphasia","Dementia","Communication","Frontotemporal Dementia","Alzheimer Disease","2026-05-27",{"date":523,"type":34},"2026-06-01",{"date":525,"type":34},"2024-08-23",{"date":527,"type":21},"2028-07-15",{"name":40,"class":41},{"id":530,"slug":531,"hasResults":12,"nctId":532,"briefTitle":533,"officialTitle":534,"acronym":535,"eligibilityCriteria":536,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":537,"targetDuration":4,"studyType":22,"phases":539,"briefSummary":540,"conditions":541,"keywords":545,"overallStatus":96,"whyStopped":4,"lastUpdateSubmitDate":550,"lastUpdatePostDateStruct":551,"startDateStruct":553,"completionDateStruct":555,"leadSponsor":557,"locationsCount":558},"100523345","hospital-implementation-of-a-stroke-protocol-for-emergency-evaluation-and-disposition-100523345","NCT06094478","Hospital Implementation of a Stroke Protocol for Emergency Evaluation and Disposition","Implementation of a Stroke Protocol for Emergency Evaluation and Disposition","HI-SPEED","Inclusion Criteria:\n\n* Age \\>=18 years\n* Final diagnosis: AIS, ICH, or SAH\n\nExclusion Criteria:\n\n* Final diagnosis: TIA or stroke NOS\n* Age \\\u003C18 years\n* Comfort care measures on day 0 or 1\n* Left hospital against medical advice\n* Enrolled in clinical trial related to stroke that is competing with this study",{"count":538,"type":21},900,[24],"Most stroke patients are initially evaluated at the closest hospital but some need to be transferred to a hospital that can provide more advanced care. The \"Door-In-Door-Out\" (DIDO) process at the first hospital can take time making transferred patients no longer able to get the advanced treatments. This study will help hospitals across the US \"stand up\" new ways to evaluate stroke patients, decide who needs to be transferred, and transfer them quickly for advanced treatment.",[542,543,544],"Stroke, Acute","Ischemic Stroke, Acute","Hemorrhagic Stroke",[546,547,548,549],"interhospital transfer","quality improvement","implementation science","stroke systems of care","2026-05-18",{"date":552,"type":34},"2026-05-20",{"date":554,"type":34},"2024-10-17",{"date":556,"type":21},"2028-07-31",{"name":40,"class":41},8,{"id":560,"slug":4,"hasResults":12,"nctId":45,"briefTitle":46,"officialTitle":47,"acronym":48,"eligibilityCriteria":49,"healthyVolunteers":12,"sex":50,"minAge":17,"maxAge":4,"enrollmentInfo":561,"targetDuration":53,"studyType":54,"phases":4,"briefSummary":55,"conditions":562,"keywords":563,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":564,"lastUpdatePostDateStruct":565,"startDateStruct":566,"completionDateStruct":568,"leadSponsor":569,"locationsCount":72},"100625244",{"count":52,"type":21},[57],[59,60,61,62,63,64,65,66],"2026-05-15",{"date":550,"type":34},{"date":567,"type":21},"2026-05",{"date":70,"type":21},{"name":40,"class":41},{"id":571,"slug":572,"hasResults":12,"nctId":573,"briefTitle":574,"officialTitle":575,"acronym":4,"eligibilityCriteria":576,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":577,"enrollmentInfo":578,"targetDuration":4,"studyType":22,"phases":579,"briefSummary":580,"conditions":581,"keywords":4,"overallStatus":96,"whyStopped":4,"lastUpdateSubmitDate":584,"lastUpdatePostDateStruct":585,"startDateStruct":586,"completionDateStruct":588,"leadSponsor":590,"locationsCount":153},"100637094","phase-1-breakthrough---t1dm-and-chronic-kidney-disease-100637094","NCT07592000","Breakthrough - T1DM and Chronic Kidney Disease","Multicenter, Phase 1\u002F2 Pilot Study of Safety and Efficacy Assessment of Tegoprubart and Calcineurin Inhibitors- Free Immunosuppression Therapy for Pancreatic Islet Transplantation in Patients With T1DM and Chronic Kidney Disease","Participants are eligible for consideration for the study only if all of the following criteria apply at the time of screening Inclusion:\n\n1. Subjects 18-70 years of age.\n2. A diagnosis of T1D ≥5 years with onset of disease at \\\u003C40 years of age.\n3. Ability to provide informed consent.\n4. Able to comply with study procedures, including the requirement to utilize continuous glucose monitoring (CGM).\n5. Involvement in appropriate diabetes management in accordance with the standard of care, using an insulin pump or multiple daily injection (MDI) insulin therapy and, unable to achieve acceptable metabolic control because of the occurrence of unexplained SHEs.\n6. HbA1c level 6.5% to 9.5% inclusive.\n7. Absence of stimulated C-peptide (\\\u003C0.3 ng\u002FmL) in response to a mixed- meal tolerance test (MMTT).\n8. Chronic kidney disease stage 1, 2 or 3a\n9. Impaired awareness of hypoglycemia based on:\n\n   * IAH (HypoA-Q Impaired Awareness Subscale ≥12) and at least one level 3 SHE during the last year or\n   * IAH and time-below-range (\\\u003C70 mg\u002Fdl) ≥4% with level 2 hypoglycemia (\\\u003C54 mg\u002Fdl) ≥1% (in Diabetes Care, Jan 2025, Patrick Choudhary) or\n   * Clarke Score \\>4 or\n   * Recurrent SHE defined by two or more level 3 SHEs in the year prior to screening\n10. If female, must be surgically sterile or postmenopausal. Women of childbearing potential may be enrolled if a pregnancy test is negative at screening\u002Fbaseline. Women of childbearing potential and men with partners that are of childbearing potential must agree to use 2 forms of highly effective methods of contraception from Screening, throughout the study, and while receiving immunosuppressive therapy for the functioning graft after the conclusion of the study. Contraception use must continue for 90 days after the last administration of the study drug (see Appendix 5). Male participants must refrain from donating sperm for the duration of the study and agree to not donate sperm for 90 days after last administration of the study drug.\n\nExclusion Criteria:\n\n1. Body mass index (BMI) \\>30 kg\u002Fm2.\n2. Weight ≤40 kg.\n3. Insulin requirement \\>60units\u002Fday or \\\u003C15 units\u002Fday.\n4. Untreated and uncontrolled proliferative diabetic retinopathy.\n5. Blood pressure: systolic blood pressure (SBP) \\>140 mmHg or diastolic blood pressure (DBP) \\>90 mmHg.\n6. Chronic kidney disease stage 3b or above.\n7. Diagnosis of macroalbuminuria (ACR\\>300 mg\u002Fg creatinine).\n8. For female participants: Positive pregnancy test, presently breast-feeding, or unwillingness to use effective contraceptive measures for the duration of the study and 90 days after discontinuation. For male participants: intent to procreate during the duration of the study or within 90 days after discontinuation or unwillingness to use effective measures of contraception.\n9. History of malignancy except for completely resected squamous or basal cell carcinoma of the skin.\n10. History of a thromboembolic event (TE), known hypercoagulable state, or condition requiring long-term anticoagulation:\n\n    1. Participants with a history of clotted venous access not requiring long- term anticoagulation may be included at the Principal Investigator's discretion if they have no other history of TEs or known hypercoagulable state.\n    2. Patients on aspirin are allowed.\n11. Receiving treatment for a medical condition requiring chronic use of systemic steroids, except for physiologic replacement for example in Addison disease.\n12. Presence of ongoing active infection including tuberculosis (TB), human immunodeficiency virus (HIV), hepatitis B, hepatitis C. Laboratory evidence of active infection even in the absence of clinical symptoms of infection is exclusionary.\n13. Invasive aspergillus, histoplasmosis or coccidioidomycosis infection within one year prior to Screening.\n14. Negative screen for Epstein-Barr Virus (EBV) by immunoglobulin G (IgG) determination.\n15. Current treatment with any immunosuppressive regimen, and treatment with biologic immune modulating agents, JAK inhibitors, S1P receptor agonists, azathioprine, 6- MP, or systemic corticosteroids.\n16. Baseline PRA over 40%\n17. Previous organ transplant (except failed pancreas or islet transplant)\n18. Persistent elevation of serum aspartate aminotransferase (AST) or alanine aminotransferase (ALT) value greater than 3 times the upper limit of normal (ULN); elevation of total bilirubin \\>1.5 ULN.\n19. Any history of receiving experimental cell or gene therapy. Exposure to any other experimental or investigational agent within 30 days or 5 half-lives; whichever is longer.\n20. History of substance abuse within the past 6 months.\n21. Severe cardiovascular disease characterized by any one of these conditions: a) stroke; b) recent myocardial infarction (within past 6 months); c) evidence of ischemia on functional cardiac exam within the last year; d) left ventricular ejection fraction\\\u003C30%.\n22. Significant hyperlipidemia despite medical therapy defined as fasting low-density lipoprotein (LDL) cholesterol \\>130 mg\u002FdL and\u002F or triglycerides \\>200 mg\u002FdL.\n23. Baseline Hb below the lower limits of normal at the local laboratory; lymphopenia (\\\u003C1,000\u002FµL), neutropenia (\\\u003C1,500\u002FµL), or thrombocytopenia (platelets \\\u003C100,000\u002FµL). Participants with lymphopenia are allowed if the Principal Investigator determines there is no additional risk and obtains clearance from a hematologist.\n24. Administration of live attenuated vaccine(s) within 2 months of Screening.\n25. Any previous treatment with Tegoprubart or any other anti-CD40L therapy","70 Years",{"count":300,"type":21},[114,136],"Single arm- subject treated with Tegoprubart and everolimus.\n\nThe purpose of this research is to gather information on the safety and effectiveness of investigational regimen containing 2 experimental components:\n\n* An investigational drug called Tegoprubart and\n* Human pancreatic islet cells\n\nBoth Tegoprubart and human pancreatic islet cells are considered investigational because they are not approved for use in the United States by the Food and Drug Administration (FDA). Participation in this research will last about 5 years.\n\nAssess safety, tolerability, and efficacy of transplanted islet cells and immunomodulation with Tegoprubart in combination with anti-thymocyte globulin (ATG), etanercept and with everolimus in adults with brittle T1D and chronic kidney disease (stage 2-3a).",[582,583],"Diabete Type 1","Chronic Kidney Disease","2026-05-14",{"date":550,"type":34},{"date":587,"type":21},"2026-04-29",{"date":589,"type":21},"2030-01-31",{"name":40,"class":41},{"id":592,"slug":593,"hasResults":12,"nctId":594,"briefTitle":595,"officialTitle":596,"acronym":597,"eligibilityCriteria":598,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":599,"targetDuration":600,"studyType":54,"phases":4,"briefSummary":601,"conditions":602,"keywords":606,"overallStatus":96,"whyStopped":4,"lastUpdateSubmitDate":610,"lastUpdatePostDateStruct":611,"startDateStruct":613,"completionDateStruct":615,"leadSponsor":617,"locationsCount":153},"100576143","creation-of-a-prospective-data-collecting-registry-for-genicular-artery-embolization-for-arthritis-100576143","NCT06781463","Creation of a Prospective Data Collecting Registry for Genicular Artery Embolization for Arthritis","Creation of a Prospective Data Collecting Registry for Genicular Artery Embolization for Arthritis (GAE)","GAE","Inclusion Criteria:\n\n* Patients aged \\>=18\n* Bilateral or unilateral knee pain attributed to knee osteoarthritis (KOA). For bilateral KOA patients, the more severe knee will be permitted inclusion to the registry\n* Grade 1-3 Osteoarthritis as diagnosed on standing weight-bearing knee radiographs per the Kellen-Lawrence Grading scale\n* Knee pain \\>6 months refractory to conservative medical management (Nonsteroidal anti-inflammatory drugs, acetaminophen, etc.)\n* Not eligible for surgical knee replacement or patient's personal preference to undergo Genicular Artery Embolization (GAE) for reasons such as minimally invasiveness of GAE\n\nExclusion Criteria:\n\n* Active malignancy\n* Active infection of the affected knee\n* Platelets \\\u003C50,000\u002FuL, INR \\>2.0 (unless on anticoagulation that can be reversed or performing radial\u002Fpedal access without reversal)\n* Corticosteroid injection of the affected knee within 3 months of enrollment\n* Rheumatoid arthritis or other seronegative arthropathy\n* Previous surgery (excluding arthroscopy) of the affected knee\n* Grade 4 per Kellgren-Lawrence Grading Scale of the affected knee\n* Pregnancy or expected pregnancy\n* Glomerular Filtration Rate (GFR) \\\u003C30\n* Anaphylactic reaction to iodinated contrast\n* Moderate to severe pain in other lower limb joints\n* Body weight \\>400 lbs. (prohibiting safe angiography)\n* Peripheral arterial disease of the treated extremity (Rutherford Grade 2 or greater)",{"count":52,"type":21},"1 Year","The goal of this study is to create a prospective registry (\\\u003C100 patients) to show the effectiveness of the genicular artery embolization procedure overtime in reducing bilateral or unilateral osteoarthritic knee pain as measured by Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) score.",[603,604,605],"Knee Osteoarthritis","Knee Osteoarthritis (Knee OA)","Knee Osteoarthritis (OA)",[607,608,609],"knee pain","knee replacement alternative","knee arthritis","2026-05-12",{"date":612,"type":34},"2026-05-13",{"date":614,"type":34},"2023-10-01",{"date":616,"type":21},"2028-10-01",{"name":40,"class":41},""]